<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982121</url>
  </required_header>
  <id_info>
    <org_study_id>2017-005020-14</org_study_id>
    <secondary_id>2017/2630</secondary_id>
    <nct_id>NCT03982121</nct_id>
  </id_info>
  <brief_title>Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy</brief_title>
  <acronym>ISILI</acronym>
  <official_title>ISILI (In Situ Immunotherapy of LIver Metastases): An Openlabel, Dose-finding, Phase I Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy (FOLFOX Regimen) in Patients With Colorectal Liver Metastases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the maximum tolerated dose (MTD), the recommended phase 2 dose (RP2D) and the
      toxicity profile (NCI CTCAE v5.0 and immune related adverse events) of i.t. administration of
      anti-CTLA4 antibody (ipilimumab) and TLR4 agonist (synthetic glucopyranosyl lipid A
      formulated in a stable emulsion [GLA-SE]) in colorectal LM (CRLM) in combination with
      intravenous (i.v.) administration of anti-PD-1 antibody (nivolumab) and chemotherapy (FOLFOX
      regimen).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never began because of withdrawal of the industrial partner
  </why_stopped>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Actual">February 12, 2020</completion_date>
  <primary_completion_date type="Actual">February 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter, open-label, dose-escalation combination phase 1 study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>For all the cohorts, the DLT period to determine the MTD will be 28 days</time_frame>
    <description>MTD will be determined based on the DLT definitions and identified as the maximum dose level at which less than 33% of DLT are observed in the evaluable patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommanded phase 2 dose (RP2D)</measure>
    <time_frame>RP2D will be assessed on 8 weeks</time_frame>
    <description>RP2D will be determined based on the MTD identified, on analysis of DLT defining events</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX IV + NIVOLUMAB IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX IV + GLA IT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX IV + IPILIMUMAB IT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX IV + NIVOLUMAB IV + GLA IT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX IV + NIVOLUMAB IV + IPILIMUMAB IT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LFOX IV + NIVOLUMAB IV + GLA IT + IPILIMUMAB IT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
    <description>Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 240 mg</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab 5 or 10 or 25 mg</description>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLA-SE</intervention_name>
    <description>GLA-SE 1 or 2 or 5 or 10 or 20 μg</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed colorectal adenocarcinoma.

          2. At least one CRLM

               -  measurable according to RECIST 1.1,

               -  at least &gt;2 cm in maximal diameter,

               -  visible on non-contrast enhanced computerized tomography (CT) scan or
                  ultrasonography,

               -  amenable to biopsy,

               -  and amenable to percutaneous i.t. injection.

          3. At least one other metastasis (controlateral CRLM or a distant visceral or lymph node
             metastasis)

               -  measurable according to RECIST 1.1,

               -  and amenable to biopsy.

          4. Tumor lesions located in previously irradiated areas are considered measurable if
             disease progression has been demonstrated in such lesions.

          5. Tumor liver involvement &lt;50% on baseline CT scan.

          6. Previous failure of active drug classes in mCRC (fluoropyrimidines, oxaliplatin,
             irinotecan, EGFR inhibitors [if wild-type RAS mCRC] and antiangiogenics).

          7. Representative tumor specimens at the initial diagnosis of CRC (paraffin blocks
             (preferred) or at least 10 unstained slides), with the corresponding pathology report,
             if available.

          8. Age &gt;/=18 years.

          9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

         10. Expected life expectancy &gt;3 months (no rapidly progressive disease).

         11. Adequate organ functions:

               -  Hemoglobin ≥9 g/dL or ≥5.6 mmol/L (blood cell transfusions are allowed), absolute
                  neutrophil count (ANC) ≥1.5 x 109/L, platelets ≥100 x 109/L

               -  Serum creatinine ≤1.5 X upper limit of normal (ULN) or creatinine clearance
                  (measured, or calculated per institutional standard) ≥50 mL/min for subject with
                  creatinine levels &gt;1.5 x institutional ULN (glomerular filtration rate can also
                  be used in place of creatinine or creatinine clearance)

               -  Serum total bilirubin ≤1.5 ULN or direct (unconjugated) bilirubin ≤ULN for
                  subjects with total bilirubin levels &gt;1.5 ULN

               -  AST (SGOT) and ALT (SGPT) ≤5 ULN

               -  Albumin &gt;33 g/L

               -  International normalized ratio (INR) or prothrombin time (PT) ≤1.5 ULN unless
                  subject is receiving anticoagulant therapy as long as PT or activated partial
                  thromboplastin time (aPTT) is within therapeutic range of intended use of
                  anticoagulants

         12. Female subjects of childbearing potential should have a negative urine or serum
             pregnancy test within 24 hours prior to receiving the first dose of study medication.
             If the urine test is positive or cannot be confirmed as negative, a serum pregnancy
             test will be required.

         13. Female subjects of childbearing potential should be willing to use two validated
             methods of birth control or be surgically sterile, or abstain from heterosexual
             activity for the course of the study through 7 months after the last dose of study
             medication (Reference Section 5.9.2). Subjects of childbearing potential are those who
             have not been surgically sterilized or have not been free from menses for &gt; 1 year.

         14. Sexually active male subjects unless surgically sterile, must agree to use condoms as
             an effective barrier method of contraception or abstain from heterosexual activity for
             the course of the study through 7 months after the last dose of study medication. It
             is recommended that their sexual partners use an effective contraceptive during the
             same period.

         15. Signed informed consent.

         16. Affiliation to or beneficiary of a social security system.

        Exclusion Criteria:

          1. Allergy or contraindication to oxaliplatin (including peripheral neuropathy [≥ grade
             2]), fluorouracil (including known dihydropyrimidine dehydrogenase (DPD) deficiency)
             or leucovorin or to any other study drug.

          2. Prior history of intolerance to full-dose FOLFOX regimen.

          3. History of anterior organ transplantation, including allograft stem cell
             transplantation

          4. History of interstitial lung disease

          5. Patients eligible for curative-intent local therapies (e.g., surgery or
             thermablation).

          6. Contraindication to percutaneous injection/biopsy (e.g., coagulation disorder,
             anticoagulant or antiaggregant therapy). Patients treated with low molecular weight
             heparin (LMWH) are eligible if they can interrupt their treatment for biopsies and
             i.t. injections.

          7. Concomitant administration of any other anticancer therapy during the trial treatment
             period.

          8. Prior chemotherapy, targeted therapy or radiation therapy within 2 weeks prior to
             study Day 1 or adverse events due to a previously administered agent that have not
             recovered (i.e., ≤ Grade 1) at baseline.

          9. Immunodeficiency or systemic steroid therapy equivalent to prednisolone &gt;10mg/day or
             any other form of immunosuppressive therapy within 7 days prior to the first dose of
             trial treatment.

         10. Other malignancy within 2 years prior to enrollment with the exception of curatively
             treated basal-cell carcinoma of the skin, squamous-cell carcinoma of the skin, and/or
             curatively resected in situ cervical and/or in situ breast cancers.

         11. Symptomatic active central nervous system metastases and/or carcinomatous meningitis.

         12. Active automimmune disease requiring systemic treatment within the past 3 months or a
             documented history of clinically severe autoimmune disease, or a syndrome that
             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or
             asymptomatic asthma/atopy under topical/aerosol therapies would be an exception to
             this rule. Subjects who require intermittent use of bronchodilators or local steroid
             injections would not be excluded from the study. Subjects with stable hypothyroidism
             on hormone replacement or Sjogren's syndrome will not be excluded from the study.
             Patients with controlled type 1diabetes mellitus on a stable insulin regimen may be
             eligible for this study.

         13. Active infection requiring systemic therapy.

         14. Pregnancy or breastfeeding, or inadequate contraceptive method, or expectation to
             conceive children within the projected duration of the trial, starting with the
             pre-screening or screening visit through 7 months after the last dose of trial
             treatment.

         15. Prior immunotherapy, including anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibodies (including
             ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation
             or checkpoint pathways).

         16. Clinically significant liver disease (i.e., with clinical, biological or morphological
             signs or symptoms of liver dysfunction, such as jaundice, hepatic encephalopathy,
             non-malignant ascites, radiological/endoscopic evidence of portal hypertension,
             biological evidence of liver insufficiency, etc.), including active viral, alcoholic,
             or other hepatitis, cirrhosis, severe oxaliplatin-induced sinusoidal obstruction
             syndrome (SOS) and inherited liver disease.

         17. Known active Hepatitis B virus infection (e.g., HBsAg reactive) or Hepatitis C virus
             infection (e.g., HCV RNA [qualitative] is detected) and positive Hepatitis test
             results.

         18. Known history of Human Immunodeficiency Virus (HIV) (HIV 1 and 2 antibodies) and
             positive HIV test results.

         19. Administration of a live vaccine within 30 days prior to the first dose of trial
             treatment.

         20. Any physical, psychological or social condition/reason that would preclude adequate
             follow-up or hamper patient's safety according to the investigator's opinion.

         21. Patient under guardianship or deprived of his liberty by a judicial or administrative
             decision or incapable of giving its consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

